Hematopoietic stem cells (HSCs) must navigate important cellular fate choices that include a symmetric self-renewal, symmetric commitment or undergo an asymmetric cell division where one of the cells is fated to differentiate. Alterations in this homeostatic program can lead to hematopoietic disorders and malignancies. Myelodysplastic syndromes (MDS) are a heterogeneous set of clonal disorders characterized by ineffective blood cell development. A common pathophysiologic mechanism in MDS is the presence of dysregulated hematopoietic stem and progenitor cells that fail to normally develop into the diverse set of blood cells necessary for normal function. Our laboratory and others identified MUSASHI2 (MSI2) as a central regulator of HSC and hematopoietic progenitor cell self-renewal (Kharas et al. Nature Medicine 2010). Additionally, we identified that Msi2 loss results in a defect in controlling symmetric and asymmetric division, failure to engraft and results in defective maintenance of myeloid lineage biased HSCs in part through control of the TGF? pathway (Park et al. 2014 Journal of Experimental Medicine). We found that elevated levels of MSI2 expression predicts poor outcome and using a genetic MDS mouse model that overexpresses MSI2 can drive a more aggressive MDS (Taggart et al. 2016 Nature Communications). To determine if MSI2 is part of a regulatory network, we performed proteomics and in vivo shRNA screen for functional regulators of leukemia self-renewal. Based on this screen, we identified SYNCRIP, an RNA binding protein that shares MSI2 targets and is required in leukemia stem cells (Vu et al., 2017 Nature Genetics). Our preliminary data with a conditional knockout for Syncrip indicates that it is also critical for HSC self-renewal. Our proposal will expand our focus from MSI2 to its associated regulatory network and characterize and identify new molecular determinants for HSC and HSPC symmetric self-renewal and asymmetric fate choice. We have adapted new technologies that include a barcoding, single cell RNA-seq and paired daughter HSC assays (FATE-seq). We have also develop a new way to map direct mRNA targets in HSCs called (HYPERTRIBE), (Nguyen et al. Nature Communications 2020).This proposal will identify new regulators of HSPC fate choice which will lead to novel therapeutic strategies to improve outcomes in MDS patients.
Understanding how adult blood stem cells maintain themselves is essential for developing future cellular therapies and treating blood diseases including anemias, myelodysplastic disorders and hematopoietic malignancies. Previously, we found that the MUSASHI2 gene is essential for blood stem control and elevated abundance in patients with myelodysplastic syndromes results in a poor outcome. This proposal studies the mechanisms of the MUSASHI2 regulatory network for the development of novel future therapeutic strategies.
|Jee, David; Yang, Jr-Shiuan; Park, Sun-Mi et al. (2018) Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell 69:265-278.e6|
|Kharas, Michael G; Lengner, Christopher J (2017) Stem Cells, Cancer, and MUSASHI in Blood and Guts. Trends Cancer 3:347-356|
|Kotini, Andriana G; Chang, Chan-Jung; Chow, Arthur et al. (2017) Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell 20:315-328.e7|
|Bhagat, Tushar D; Chen, Si; Bartenstein, Matthias et al. (2017) Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/?-Catenin Activation. Cancer Res 77:4846-4857|
|Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875|
|Yousefi, Maryam; Li, Ning; Nakauka-Ddamba, Angela et al. (2016) Msi RNA-binding proteins control reserve intestinal stem cell quiescence. J Cell Biol 215:401-413|
|Taggart, James; Ho, Tzu-Chieh; Amin, Elianna et al. (2016) MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nat Commun 7:10739|
|Park, Sun-Mi; Gönen, Mithat; Vu, Ly et al. (2015) Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest 125:1286-98|
|Wang, Shan; Li, Ning; Yousefi, Maryam et al. (2015) Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun 6:6517|